RWE in an evolving regulatory landscape: Using real-world evidence to support novel product development pathways

The growing interest in RWE from both regulators and payors, along with innovative data models and technologies, has the potential to transform clinical research as we know it. Particularly for rare diseases, the opportunity to utilize existing data and to link patients across multiple datasets, in concert with proven prospective research models within non-traditional infrastructure settings, offers important opportunities both to streamline the research process and also to bring the needed real-world perspective and data to the table. Real-world data also can provide important information in the post-marketing setting, especially from a safety perspective, to answer regulatory questions.

Listen to this on-demand webinar with Parexel experts Leanne Larson, Corporate Vice President and WW Head, Real-World Evidence and Amy McKee, M.D., Vice President, Regulatory Consulting Services to learn more about:

• The changing global regulatory perspective on RWE

• Utilizing RWE in synthetic control arms to support regulatory submissions

• Innovative approaches to accessing and integrating RWE today

To register, visit: https://register.gotowebinar.com/register/1820835637020873740

Previous Article
Commercial and regulatory strategy considerations for biotech
Commercial and regulatory strategy considerations for biotech

In this blog, Parexel regulatory and strategy experts tackle the question of how we can ensure that worthy ...

Next Flipbook
Using real-world evidence to help your product succeed
Using real-world evidence to help your product succeed

Let us show you how our experience of leveraging real-world data (RWD) and real-world evidence (RWE) can he...